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Abstract The human immunode¢ciency virus-1 (HIV-1) Tat
protein was previously reported to compete the association of
PA28 regulator with the K rings of the 20S proteasome and to
inhibit its peptidase activity. However, the distinct interaction
sites within the proteasome complex remained to be determined.
Here we show that HIV-1 Tat binds to K4 and K7, six L sub-
units of the constitutive 20S proteasome and the interferon-Q-
inducible subunits L2i and L5i. A Tat^proteasome interaction
can also be demonstrated in vivo and leads to inhibition of
proteasomal activity. This indicates that Tat can modulate or
interfere with cellular proteasome function by speci¢c interac-
tion with distinct proteasomal subunits.
, 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Human immunode¢ciency virus-1 (HIV-1), a retrovirus of
the lentivirus subgroup, causes the debilitating and generally
fatal disease AIDS (acquired immune de¢ciency syndrome).
The HIV-1 Tat protein, an 86 amino acid protein, is essential
for virus replication. It is an RNA binding protein and an
activator of transcription. Tat has been shown to be involved
in the progression of HIV infection by immunosuppression,
induction of apoptosis of T cells, inhibition of phagocytosis of
apoptotic tumour cells by accessory cells, and by suppression
of antigen-driven T-cell proliferation [1]. Possibly, HIV pro-
teins including Tat may prevent the correct processing and
presentation of tumour-associated and viral antigens by the
major histocompatibility (MHC) class I pathway.
An important component of the MHC class I immune re-
sponse is the ubiquitin^proteasome system, the central proteo-
lytic system of eukaryotic cells [2]. Besides generating antigen-
ic peptides, the major functions of the proteasome are the
selective ATP-dependent degradation of cytosolic, nuclear
and membrane-bound proteins [3], as well as the regulation
of important cellular processes such as cell cycle progression,
transcription, di¡erentiation, apoptosis and the cell stress re-
sponse [4^6].
The proteasome is a multicatalytic protease complex con-
sisting of a 20S catalytic core bound to regulatory complexes.
The 20S core particle, exhibiting the proteolytic activity, con-
sists of seven di¡erent K and seven di¡erent L subunits ar-
ranged in four heptameric rings giving an K7L7L7K7 order.
Three of the seven L subunits (L1, L2, L5) in the two inner
rings are catalytically active and can be replaced by their
cytokine-inducible counterparts L1i (LMP2), L2i (Mecl1)
and L5i (LMP7) [7]. Incorporation of immunosubunits into
the complex can modulate the proteolytic characteristics of
the 20S proteasome representing an important mechanism
for the e⁄cient generation of antigenic peptides [4].
The larger 26S proteasome consists of the central 20S core
particle capped on both ends by a 19S regulatory complex
that is essential for recognition and degradation of ubiqui-
tin^protein conjugates in an ATP-dependent manner [8]. Eu-
karyotic cells also contain another particle called the 19S-20S-
PA28 hybrid proteasome. This complex consists of the central
20S core particle capped on one end by the 19S regulator and
on the other by a complex known as PA28 activator. PA28,
whose synthesis is induced by interferon-Q (IFNQ), was previ-
ously shown to play an important role in antigen processing
by the MHC class I pathway [4].
In previous work it was shown that the Tat protein inhibits
the catalytic activity of the 20S proteasome in vitro [9], inter-
feres with proteasomal antigen processing by competing the
PA28 binding to the 20S proteasome and that it shares a
common binding site with the two subunits of PA28 on the
20S proteasome [10].
However, so far the subunits of the 20S proteasome that
interact with Tat still remain to be de¢ned. Here we present
the ¢rst experimental evidence that HIV-1 Tat interacts spe-
ci¢cally with two of the seven K subunits (K4 and K7), several
L subunits of the constitutive proteasome and two L subunits
of the immunoproteasome. Furthermore, our in vivo experi-
mental data show that Tat a¡ects the catalytic activity of the
proteasome complex through direct binding.
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2. Materials and methods
2.1. Preparation of expression vectors
The seven human K subunit cDNAs were ampli¢ed by reverse tran-
scription-polymerase chain reaction (RT-PCR) and cloned into the
pCite vector (Novagen) in the correct reading frame resulting in con-
structs pCite-K17. The cDNAs of the 10 di¡erent human L subunits
were obtained by RT-PCR and ligated in frame into the NotI and
BamHI sites of plasmid pIVEX2.3_MCS (Roche Molecular Biochem-
icals) for expression of untagged proteins. The HIV-Tat cDNA was
cloned into BamHI sites of vectors pET41 (Novagen) and pEGFP-C1
(Clontech), ensuring selection of the correct reading frame. All result-
ing constructs were sequenced to con¢rm identity and PCR ¢delity.
2.2. Expression, puri¢cation and binding analysis of recombinant
proteins with proteasomes
Transformed Escherichia coli strain BL21 (Stratagene) was grown at
37‡C in kanamycin-containing LB medium until the logarithmic phase
(OD600 at 0.6) and induced with 1 mM IPTG for 1 h. Cells were
harvested by centrifugation, resuspended in phosphate-bu¡ered saline
containing 1% (v/v) Tween and were disrupted by a French press.
Glutathione S-transferase (GST)- or GST-Tat-containing protein ex-
tracts were incubated with glutathione (GSH)-Sepharose beads
(Amersham Pharmacia Biotech) and puri¢ed according to the manu-
facturer’s protocols.
For in vitro transcription/translation the single tube protein system
3 (STP3) kit (Novagen) was used according to the manufacturer’s
instructions.
For binding studies with radiolabelled subunits, equal amounts (9
Wg) of GST or GST-Tat proteins were immobilised onto GSH-Sephar-
ose beads and processed as described [11]. For interaction studies of
the 20S proteasome and Tat, immobilised GST or GST-Tat proteins
were incubated 2 h at 4‡C with 50 Wg of 20S proteasome, washed with
di¡erent concentrations of salt as indicated and ¢nally eluted from the
beads using GSH.
The synthesised or eluted proteins were analysed by sodium dodecyl
sulphate^polyacrylamide gel electrophoresis (SDS^PAGE) [12] fol-
lowed by Western blot, Coomassie staining or phospho-imager anal-
yses (Fuji¢lm FLA-2000R).
2.3. Cell culture and transfection
Human HeLa and T2 cells were cultivated under standard condi-
tions in RPMI medium containing 10% foetal calf serum, 2 mM
L-glutamine and 100 U/ml penicillin/streptomycin. HeLa cells were
transfected with the green £uorescent protein (GFP)-Tat expression
plasmid or the GFP control plasmid using FuGENE 6 transfection
reagent according to the manufacturer’s instructions (Roche Molec-
ular Biochemicals).
2.4. Sucrose gradient fractionation, immunoprecipitation, and Western
blot analyses
Cell extracts were fractionated by velocity gradient ultracentrifuga-
tion as described [13]. Equal amounts of protein were subjected to
immunoprecipitation and processed according to a previously de-
scribed protocol [14]. The precipitates were separated by SDS^
PAGE, transferred onto polyvinylidene di£uoride membranes by elec-
troblotting and immunodetected as described [13].
Antibodies against proteasomal subunits were kindly provided by
K. Hendil (Copenhagen). The anti-proteasome antiserum MP3 is lab-
oratory stock and has been described previously [13]. The monoclonal
anti-GFP is available from BabCo. The polyclonal anti-Tat antibody
was raised against a peptide corresponding to the core region of the
Tat protein (48GRKKRRQRRRPPQGSQ63).
2.5. 20S proteasome preparation and measurement of proteolytic
activity
20S proteasomes were puri¢ed from calf liver and human T2 cells
by standard procedures [15]. Chymotryptic activity of the proteasome
was assessed using the synthetic peptide substrate Suc-Leu-Leu-Val-
Tyr-aminomethylcoumarin as described [10].
3. Results
3.1. Interaction of the GST-Tat protein with the 20S
proteasome
To demonstrate an interaction between the HIV-1 Tat pro-
tein and the 20S proteasome, we expressed a recombinant
GST-Tat protein in bacteria. The GST fusion protein and
GST alone were immobilised on GSH beads and incubated
with puri¢ed 20S proteasomes. The beads were then washed
and the eluted proteins were analysed by Western blotting
(Fig. 1A). As evidenced by Coomassie staining and immuno-
blotting with an antibody directed against the anti-K3 subunit,
GST-Tat is able to trap 20S proteasomes while GST alone
shows no binding (Fig. 1A).
To dissect the speci¢city and stringency of the Tat^
proteasome interaction the beads loaded with GST-Tat and
bound proteasome were washed with increasing concentra-
tions of KCl (80 mM, 300 mM, 480 mM, and 600 mM).
Proteins that remained bound were eluted from the beads
by GSH and analysed by SDS^PAGE. Even at a concentra-
tion of 600 mM KCl the proteasomes still remained bound to
the HIV-1 Tat protein supporting the speci¢city of the inter-
action (Fig. 1B). The results con¢rm the previous observa-
tions that Tat protein directly interacts with the 20S protea-
Fig. 1. Interaction of HIV-1 Tat protein with 20S proteasome in vi-
tro. A: Immobilised GST-Tat (lane 1) or GST (lane 3) was incuba-
ted with 20S proteasomes from T2 cells (proteasome loading con-
trol; lane 2) and eluted proteins were detected by Western blot with
an anti-K3 antibody (lanes 1^3). Coomassie staining control of 20S
proteasomes (lane 4). B: Immobilised GST-Tat (upper panel, lanes
1^5) or GST (lower panel, lanes 1^5) was incubated with puri¢ed
20S proteasomes from calf liver and washed consecutively with 80,
300, 480, or 600 mM KCl, and ¢nally eluted with GSH. Proteins
were separated by SDS^PAGE and detected by Coomassie staining
with respective molecular weight markers on the right.
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some [9] and that our recombinant GST fusion protein is
functional.
3.2. Interactions of immobilised GST-Tat with distinct
proteasomal K and L subunits in vitro
Based on the observation that Tat competes PA28 binding
it had been proposed that the interaction of HIV-Tat with 20S
core particle occurs via the K ring structure. To dissect which
of the 20S proteasome subunits binds to Tat each individual K
and L subunit was tested for interaction with the Tat protein.
With this aim all proteasomal K and L subunits were cloned
into expression vectors and translated in vitro in the presence
of [35S]methionine using a transcription/translation system
(Figs. 2A and 3A). To identify the subunits that are able to
interact with Tat, in vitro translated 35S-radiolabelled K sub-
units were incubated with immobilised GST-Tat (Fig. 2C) or
with GST as control (Fig. 2B). Immobilised Tat protein
bound speci¢cally to the K4 and K7 subunits while a weak
interaction was also found with the K2 and K6 subunits (Fig.
2B). No interaction was detected with the other K subunits or
GST alone (Fig. 2B,C).
Surprisingly, immobilised Tat bound strongly to six consti-
tutive L subunits (L1, L2, L3, L5, L6 and L7) and two immuno-
L subunits (LMP7/L5i and Mecl1/L2i) (Fig. 3C). No interac-
tions were found with L4 and LMP2/L1i or GST alone (Fig.
3B). This result was completely unexpected, since so far Tat
was thought to bind only to the K ring subunits [10].
3.3. HIV-Tat interacts with 20S proteasomes and inhibits
peptidase activity in vivo
To con¢rm the observed Tat^subunit interactions and the
possible consequences for proteasome function in vivo human
HeLa cells were transiently transfected with a GFP-tagged
version of HIV-Tat or with GFP as a control. Cellular lysates
Fig. 2. Interactions of GST-Tat protein and proteasomal K subunits.
A: In vitro translated 35S-radiolabelled K subunits. B,C: The bind-
ing of in vitro translated 35S-radiolabelled K subunits to immobilised
GST (B) or GST-Tat (C). The positions of relevant molecular
weight markers are shown on the left.
Fig. 3. Interactions of GST-Tat protein and proteasomal L subunits.
A: In vitro translated 35S-radiolabelled L subunits. B,C: The bind-
ing of in vitro translated 35S-radiolabelled L subunits to immobilised
GST (B) or GST-Tat (C) was evaluated. The positions of relevant
molecular weight markers are shown at the left.
Fig. 4. Co-migration of GFP-Tat with 20S proteasomes and inhibi-
tion of proteolytic activity. Sucrose gradient fractionation of cellular
extracts from GFP-Tat (A) and GFP-transfected cells (B). Fraction
1 corresponds to the top (10% sucrose) and fraction 20 to the bot-
tom (40% sucrose) of the gradient. Gradient fractions were analysed
by Western blotting for L1 and GFP. C: Chymotrypsin-like activity
from 10 Wl of each gradient fraction containing 20S proteasomes
from GFP-Tat-transfected (rhombi) and GFP-transfected cells (tri-
angles).
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of these transfected cells were fractionated by sucrose gradient
ultracentrifugation and fractions were analysed by immuno-
blotting for GFP-Tat and 20S proteasomes. GFP-Tat indeed
co-migrated with 20S proteasomes in fractions 10^12 (Fig.
4A) whereas GFP alone did not migrate in these 20S fractions
(Fig. 4B) and was only found on the top of the gradient (data
not shown). Similar results were obtained with IFNQ-stimu-
lated cells where GFP-Tat sedimented in the same fractions
with LMP7 (data not shown). Assaying the proteolytic activ-
ity in the gradient fractions reveals that cellular interaction of
GFP-Tat with proteasomes results in maximum 80% inhibi-
tion for the chymotryptic activity of 20S proteasomes (Fig.
4C).
For direct proof of an in vivo interaction pull-down experi-
ments were carried out using a polyclonal anti-proteasome
antibody (MP3) and a monoclonal anti-L7 antibody with
pooled gradient fractions containing 20S proteasomes and
Tat. The proteins co-immunoprecipitated from the fractions
with MP3 were further analysed by immunoblotting using a
monoclonal anti-GFP antibody. Immunoblot analysis of
MP3-precipitated proteins from gradient fractions 9^11 re-
vealed a band of approximately 41 kDa corresponding to
the GFP-Tat fusion protein (Fig. 5, lanes 2 and 3). No co-
immunoprecipitated proteins were found in HeLa cells trans-
fected with GFP alone (Fig. 5, lane 1). Identical results were
obtained after immunoprecipitation using the anti-L7 anti-
body and immunoblot analysis with a polyclonal anti-Tat
antibody (Fig. 5). The anti-GFP antibody vice versa immuno-
precipitated proteasomal subunits detected in immunoblots by
the MP3 antibody (Fig. 5, lane 4). Together these data show
that HIV-Tat when expressed in HeLa cells associates with
20S proteasomes and impairs proteasomal activity.
4. Discussion
The HIV-1 Tat protein has pleiotropic roles in infected
cells. The manipulation of the 26S proteasome by Tat is one
of the intracellular activities of Tat [9,10]. A recent study has
reported that Tat and the subunits of the PA28 regulator
share a similar site for binding the K subunits of the 20S
proteasome [10]. However, the distinct subunits of the 20S
proteasome that bind to Tat had not been identi¢ed. We
have now demonstrated a direct interaction of two K subunits,
six constitutive L subunits and two immuno-L subunits with
Tat in vitro (Figs. 2 and 3).
The binding of the Tat complex to the K subunits blocks
binding of the PA28 regulator thereby interfering with antigen
presentation [10]. Our results extend these ¢ndings by identi-
fying the K subunits that bind directly to Tat (Fig. 2). Inter-
estingly, the crystal structure of a PA28^20S complex shows
that seven tail-like projections of the 11S regulator bind
equally to pockets located between proteasomal K subunits
forcing conformational changes in the proteasomal K subunits
incompatible with the closed gate conformation [16]. These
interactions might be prevented by Tat binding to the K4
and K7 subunits of the proteasome. Interestingly, the hepatitis
B virus HbX protein also binds to the K4 subunit and inter-
feres with PA28 regulator binding [17,18] indicating an impor-
tant role for K4 in proteasome function.
Moreover, our experiments show that Tat binds to six L
subunits of the constitutive 20S proteasome and two L sub-
units of the immunoproteasome (Fig. 3). The binding of Tat
to L subunits may in£uence proteasomal catalytic activity for
instance as an allosteric e¡ector or by a¡ecting its cellular
distribution. However, mapping of the interaction site within
the L subunits or the complex will be a future challenge.
Several other viral proteins bind to proteasomal L subunits.
HIV Nef interacts with L7 and down-regulates intracellular L7
levels [19]. Furthermore, NF-UB/p105 processing by the pro-
teasome is a¡ected by the human T cell leukaemia virus Tax
protein which binds to L7 as well as to K3 [20]. The combined
observations suggest that viral proliferation and morphogen-
esis may capitalise on the manipulation of proteasomal cata-
lytic activity as we observed a dramatic decrease of the chy-
motrypsin activity of the 20S proteasome in GFP-Tat-
transfected cells in vivo (Fig. 4C). Proteasome inhibition by
GFP-Tat is also mirrored by the stabilisation of proteasomal
substrates such as IUBK (our unpublished results).
In summary, HIV-Tat in£uences proteasome function in
two ways: (1) by interfering with binding of the PA28 regu-
lator to the K ring by interaction with K4 and K7, and (2) by
blocking the proteolytic activity of the proteasome in vivo by
direct interaction with the L subunits thereby contributing
directly to the immune escape of the virus.
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